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Helicobacter pylori (H. pylori) causes gastric mucosa inflammation and gastric cancer
mostly via several virulence factors. Induction of proinflammatory pathways plays a
crucial role in chronic inflammation, gastric carcinoma, and H. pylori pathogenesis. Herbal
medicines (HMs) are nontoxic, inexpensive, and mostly anti‐inflammatory reminding
meticulous emphasis on the elimination of H. pylori and gastric cancer. Several HM has
exerted paramount anti‐H. pylori traits. In addition, they exert anti‐inflammatory effects
through several cellular circuits such as inhibition of 5ʹ‐adenosine monophosphate‐
activated protein kinase, nuclear factor‐κB, and activator protein‐1 pathway activation
leading to the inhibition of proinflammatory cytokines (interleukin 1α [IL‐1α], IL‐1β, IL‐6,
IL‐8, IL‐12, interferon γ, and tumor necrosis factor‐α) expression. Furthermore, they
inhibit nitrous oxide release and COX‐2 and iNOS activity. The apoptosis induction in
Th1 and Th17‐polarized lymphocytes and M2‐macrophagic polarization and STAT6
activation has also been exhibited. Thus, their exact consumable amount has not been
revealed, and clinical trials are needed to achieve optimal concentration and their
pharmacokinetics. In the aspect of bioavailability, solubility, absorption, and metabolism
of herbal compounds, nanocarriers such as poly lactideco‐glycolide‐based loading and
related formulations are helpful. Noticeably, combined therapies accompanied by
probiotics can also be examined for better clearance of gastric mucosa. In addition,
downregulation of inflammatory microRNAs (miRNAs) by HMs and upregulation of
those anti‐inflammatory miRNAs is proposed to protect the gastric mucosa. Thus there
is anticipation that in near future HM‐based formulations and proper delivery systems
are possibly applicable against gastric cancer or other ailments because of H. pylori.
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1 | INTRODUCTION
Helicobacter pylori (H. pylori) is a Gram‐negative spiral‐shaped micro-
organism, which grows in microaerophilic conditions and is capable of
colonizing the epithelial lining of the human stomach (Forgacs, 1996;
Hill, 1997). Along the years, H. pylori have coevolved within the human
host and retained its adaptation to survive under the acidic gastric
milieu of the human stomach. It has been estimated that almost half of
J Cell Physiol. 2019;1–14. wileyonlinelibrary.com/journal/jcp © 2019 Wiley Periodicals, Inc. | 1
the world’s population are infected with H. pylori, as a Class I
carcinogen accentuating its pervasiveness throughout the society.
Very recently, a meta‐analysis on the worldwide prevalence of H. pylori
has revealed that the infection was more prevalent in developing
countries as compared with the developed countries. Although being
widespread worldwide, the highest H. pylori infection rate has been
reported from Latin America and the Caribbean, whereas Northern
America had the lowest rate of infection. Although the exact route of
transmission for H. pylori infection remains unclear, a mounting body
of evidence bolsters person to person or the contents of the stomach
aerosol transmission either via oral–oral or fecal–oral (Naumann,
Sokolova, Tegtmeyer, & Backert, 2017). Eventually, the pathogen
colonizes both the corpus and antrum simultaneously within the
stomach. In this respect, chronic infection with H. pylori may lead to
serious complications such as gastritis, peptic ulcer disease, gastric
cancer, mucosa‐associated lymphoid tissue, B‐cell lymphoma, and
gastric adenocarcinoma (Thorell et al., 2017). H. pylori is resistant to
gastric acid and its pathogenesis is exerted via urease, lipopolysac-
charide, and toxins such as vacuolating toxin (vacA), carcinogenic toxin
(cagA) and some other proteins, which lead to the gastric inflammation
and epithelial damage or two types of gastric cancer (Malekzadeh
et al., 2000; Malfertheiner et al., 2002; Press, 2009). Therefore,
hindering of the process of H. pylori pathogenesis using efficient
therapeutic approaches is a chief requirement. Because H. pylori
infection leads to increase in proinflammatory cytokines/chemokines
(interleukin 1 [IL‐1], IL‐6, IL‐8, interferon γ [INF‐γ], tumor necrosis
factor α [TNF‐α]) and proteins, hence the application of anti‐
inflammatory compounds play a pivotal role in chronic gastritis and
cancer prevention. In general, H. pylori strains are susceptible to some
antibiotics in vitro but only a small number of these antibiotics, such as
Clarithromycin, Metronidazole, Amoxicillin, Tetracycline, etc., are used
in vitro to successfully eradicate this bacterium (Megraud, 1997).
Probably the reason for this is the presence of bacteria that remained
under the mucin so that only antibiotics, which can penetrate the
infected mucosa are effective (Szajewska, Horvath, & Kołodziej, 2015).
Although this bacterium is susceptible to some antimicrobial agents in
vitro, the successful eradication of this bacterium is considered a major
challenge (Feng, Wen, Zhu, Men, & Yang, 2016). Noticeably, applica-
tion of gastroprotective herbal medicine (HM) bioactive compounds
(particularly tannins, acting as a protective layer over epithelial cells) is
a promising approach owing to limitations in long‐term consumption of
synthetic drugs. Very little is known regarding anticancer and anti‐
inflammatory HM bioactive compounds with anti‐H. pylori properties.
2 | THE RECOMMENDED TREATMENT
REGIMENS FOR H. pylor i
First‐line treatment regimen: A triple regimen/therapy (TT) containing
proton pump inhibitor (PPI) + clarithromycin + amoxicillin or metroni-
dazole, which was first introduced by Maestricht I as an effective
treatment regimen for the eradication of H. pylori infection worldwide
(Malfertheiner et al., 2006; Osato, Reddy, Reddy, Penland, & Graham,
2001). Second line treatment regimen: A quadruple therapy containing
PPI + bismuth + tetracycline +metronidazole and third‐line treatment
regimen, which is based on the antibiotic susceptibility testing though
not responding in 20–30% of patients (Gerrits, de Zoete, Arents,
Kuipers, & Kusters, 2002; Kwon et al., 2000).
2.1 | First‐line treatment
If the resistance to clarithromycin is low 15–20% it is better to use the
first‐line treatment regimen (Lochmannova, 2010). If metronidazole
tested for resistance be less than 40%, then metronidazole can be used
instead of amoxicillin. The success of the 14‐day course of the first‐line
of treatment is more than that of the 7‐day period (Howden & Hunt,
1998; Malfertheiner et al., 2006). Although the treatment is considered
first‐line treatment, today the amount of eradication is low and not
very effective. The most important factor is the antibiotic resistance of
H. pylori especially to the clarithromycin antibiotic in recent decades
(Mégraud & Lamouliatte, 2003; O’Connor, Gisbert, McNamara, &
O’Morain, 2010). Metronidazole has a therapeutic advantage compared
with clarithromycin, which is beneficial in eliminating the infection,
despite the increased resistance of H. pylori to this antibiotic. In
addition, the possibility of resistance to clarithromycin and therapeutic
failure is very high. Among other factors effective in H. pylori
eradication, the patient’s intolerance to the drug, low gastric pH, and
high number accumulation of bacteria in the stomach and duodenum
can be stated (Mégraud & Lamouliatte, 2003; O’Connor et al., 2010).
Approximately 5–35% of patients with H. pylori infection do not
respond to treatment with first‐line antibiotics (Leung & Graham, 2002;
Mégraud & Lamouliatte, 2003). In this case, a quadruple therapy
regimen containing bismuth (Lemos et al., 2012) instead of the first‐line
treatment can be used (Howden & Hunt, 1998; Leung & Graham,
2002). In case of resistance, an antibiotic susceptibility testing is
advantageous following the first‐line failure (Fallahi & Maleknejad,
2007). Generally, first‐line treatment should be simple, tolerable, and
affordable (Malfertheiner et al., 2002).
2.2 | Second‐line treatment
The second‐line treatment after the first‐line treatment failure or in the
case of allergy to penicillin compounds, the quadruple therapy regimen
containing bismuth plus tetracycline, metronidazole, and acid inhibitors
(PPI) are the best choice (Howden & Hunt, 1998). Bismuth‐based diets,
especially when prescribed with PPI, may also be sufficient for 1 week.
This diet is widely used in Iran with regard to affordable and effective
effects. Bismuth acts on its antimicrobial effects by disturbing the cell
wall and increasing its permeability. Changing the color of the tongue,
feces, and possible neurological toxicity during the course of
its consumption is a complication that can be improved by the
discontinuation of the drug. But some believe that the diet is not a
good regimen because of the long course of treatment, side effects, high
levels of tablets per day, and the lack of available bismuth. If bismuth is
not available, then the drug can be converted into a three‐dimensional
regimen and can be used as second‐line (Malfertheiner et al., 2002;
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Vaz Coelho, Friche Passos, Chausson, & Castro, 1991). In the absence of
tetracycline, it can be replaced by amoxicillin (Howden & Hunt, 1998). If
a second‐line treatment in primary care failed by a general practitioner,
the patient should be referred to a specialist to be diagnosed with
antibiotics with a sample taken from the mucosa and antibacterial
testing and adoption of antibiotic choice (Malfertheiner et al., 2002).
2.3 | Third‐line treatment
The antimicrobial susceptibility test is expensive and not performed
extensively in all areas, and more important this test is performed
during the upper gastrointestinal endoscopy, which is costly, well
tolerated by all patients and not indicated in many cases (such as
uninvestigated indigestion). Therefore, in the current clinical practice,
the role of antimicrobial susceptibility test is drawn to the margin.
However, because of the increasing prevalence of antibiotic resistance,
the successful eradication of these organisms requires the consumption
of low‐resistance antibiotics, which requires extensive research to
determine the antibiotic resistance of H. pylori in different geographical
areas and antibiotic susceptibility testing. The rate of eradication of
H. pylori with the experimental and nonscientific diets is lower than the
optimal and desirable level. On the other hand, according to studies,
the rate of eradication of this bacterium by performing antibiotic
susceptibility tests is high (83–99%), highlighting the need for antibiotic
susceptibility testing to successfully eradicate H. pylori. According to the
published guidelines, antibiotic susceptibility testing is performed if the
treatment fails twice. Treatment of the third‐line after antibiotic
susceptibility testing should contain twice daily PPI and at least two
effective antibiotics for 1 to 2 weeks. Bismuth subsalicylate can also be
used as a fourth‐line treatment (Gisbert & Pajares, 2005; Nishizawa,
Suzuki, & Hibi, 2009; O’Connor et al., 2010; Roghani, Massarrat,
Shirekhoda, & Butorab, 2003). Novel therapeutic and vaccination
approaches such as bismuth‐containing quadruple therapy with
metronidazole and amoxicillin (Q. Chen et al., 2016), herbal extracts,
such as berberine (Huang et al., 2015) and other traditional medicines,
probiotics combination therapies, nanoparticles, novel drug‐delivery
methods have been evaluated in this regard (Safavi, Sabourian, &
Foroumadi, 2016). Phytotherapy is a promising alternative therapy,
particularly due to its naturality, least side effects, low toxicity, and
inexpensiveness as compared over the chemical therapy.
3 | EFFICACY OF HM AGAINST H. pylor i
HIGHLIGHTING THEIR
ANTI ‐ INFLAMMATORY AND ANTICANCER
CELLULAR PATHWAYS
HM has been applied for centuries and has recently been used in the
treatment of various diseases in the development of new anticancer
drugs as plant antibiotics and even prebiotics. According to studies,
the most potent anti‐H. pylori HM in vitro were Carum carvi L. and
ethanolic extract of Thymus zygis L. each with minimum inhibitory
concentration (MIC) of 0.3 µl/ml, followed by ethanolic extract of
Hydrastis canadensis L (MIC = 0.78–50 µg/ml), and chloroform extract
of Centaurea solstitialis L and Chromolaena odorata L (MIC for each
being 1.95 µg/ml). In addition, two studies have evaluated minimum
bactericidal concentrations (MBCs) including Camellia sinensis (L.)
Kuntze (MBC= 4mg/ml) and Chenopodium ambrosioides L. (MBC= 5
mg/ml; Cogo et al., 2010; Nariman, Eftekhar, Habibi, Massarrat, &
Malekzadeh, 2009; Nostro et al., 2005). Noticeably, apart from all the
discomforts and illnesses, HMs are even used as inexpensive, safe, and
nontoxic complementary or alternative anti‐H. pylori formulations,
particularly against those drug‐resistant strains. It was found that
conventional therapy by Chinese herbal medicine had reduced the
mortality rate due to gastric cancer by 45% (Hung et al., 2017). The
major mechanisms exerted by HM include blocking the serotonin
2b/2c receptor pathway (Japanese formula), suppression of the
signaling circuits of nuclear factor‐κB (NF‐κB), and mitogen‐activated
protein kinases in lipopolysaccharide‐induced macrophage cells (Radix
Astragali and Os Sepiae and Kampo medicine), hefA efflux pump gene
suppression (emodin, baicalin, schizandrin, and berberine), cell
membrane disruption, and hindering the bacterial DNA, RNA, and
protein biosynthesis, and degradation of endotoxins (Radix scutellariae),
inhibiting bacterial proliferation and respiration, suppressing the
oxidation of glucose and sugar metabolic intermediates
(Rhizoma coptidis), H. pylori amine‐N‐acetyl transferase inhibition
(emodin), destroying the proton motive force and enzymes (by
hydroxyl group of carvacrol in (Satureja bachtiarica; Falsafi et al., 2015).
The decrease in MIC of amoxicillin and tetracycline (by emodin
baicalin, schizandrin, and berberine; Huang et al., 2015) and the
decrease of resistance rate against clarithromycin (Myrtus communis,
Teucrium polium extracts) have been also observed. The latter
extracts inhibit mutations and thereby hinder resistance develop-
ment. An ellagitannin‐rich fraction from Eucalyptus citriodora (ECF)
exerted marked gastroprotective effect by reducing the proinflam-
matory markers; IL‐1β, TNF‐α, 5‐LO, and COX‐2 and also caspases‐3
tissue levels in rat model study.
HMs contain some major active compounds including alkaloids
(nitrogen‐bearing molecules acting as anti‐infective agents), antho-
cyanins (for blood vessel health), anthraquinones (in Chinese herbs
for large intestine health), bitters (for GI function improvement),
triterpenoids (anticancer and anti‐inflammatory), glycosides (remark-
able effect on cardiac function), coumarins (for muscle function),
coumarins (anticancer and anti‐inflammatory), flavonoids (anti‐
inflammatory effects), glucosilinates (wound and joint healing),
phenols (such as that in thyme acting as antiseptic and anti‐
inflammatory), tannins (anti‐infective agents), vitamins (remarkable
health effects), taxol (anticancer), vincristine (anticancer), terpenes
(anti‐infective), Antimicrobial peptides, and volatile oils (various
effects such as anti‐infective and anti‐inflammatory; Liu et al.,
2018). Those major anticancer compounds entered in clinical trials
include taxanes, camptothecins, vinca (or Catharanthus), and
epipodophyllotoxins. The vinca alkaloids, taxanes (including paclitax-
el), and other semisynthetic fractions disrupt tubulins the mitosis in
metaphase of the cell cycle (R. C. Wang et al., 2017). In addition, a
recent mass spectroscopy analysis demonstrated major compounds
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of HMs including niaziridin, glycyrrhizin, piperine, zingiber officinale,
Cuminum cyminum, C. carvi, Stevia rebaudiana, lysergol, allicin, Aloe
vera, curcumin, genistein, ammannia multiflora, naringin, quercetin,
capsaicin, and sinomenine (A. Zhang, Sun, & Wang, 2018). Further-
more, some major anti‐inflammatory HM compounds with clinical
trial included Qingchang Wenzhong Decoction, which alleviated
colitis‐associated inflammation, Erchen decoction (ECD), and Lin-
guizhugan decoction acting by TNF‐? and insulin pathway, macro-
phage‐stimulating protein (MSP) upregulation, Recepteur d’Origine
Nantais expression, reducing the protein kinase B/ (pAkt/Akt,
phosphorylated [p] Akt) levels and claudin‐2 expression and enhance
the zona occluden 1 expression. Moreover, the regulation of
inflammatory pathways or cytokines was exerted by roots of
Glycyrrhiza uralensis Fisch Scutellaria baicalensis Georgi, the fruit of
Ziziphus jujuba Mill and Paeonia lactiflora Pall.
Studies have revealed that nontoxic molecule curcumin has a wide
spectrum of beneficial properties for example, antioxidant, anticancer,
anti‐inflammatory, antiproliferative, anti‐fungal, and antimicrobial (Ak-
ram et al., 2010). Curcumin anti‐H. pylori properties as a potential
therapeutic candidate include anti‐carcinogenesis activity through
inhibition of I‐κB kinase and expression of NF‐κB and survival of gastric
mucosa and inhibition of cell apoptosis induced by H. pylori Type IV
secretion system. It exerts astonishing anti‐inflammatory power through
the inhibition of COX‐2, LOX, iNOS, and production of cytokines such as
IFN‐γ and TNF‐α (Sarkar, De, & Mukhopadhyay, 2016). Furthermore,
curcumin inhibits production of inflammatory cytokines for example, IL‐
1β, IL‐6, and TNF‐α, and downregulates the protein kinase C hindering
cancer cell growth. It has also anticancer effects via apoptosis (Caspase
activation, p21 expression or p53 signaling and release of cytochrome‐C;
Haghi, Azimi, & Rahimi, 2017; Larussa et al., 2017).
In addition, curcumin has profound anticancer effects as depicted
in Table 1. The curcumin is a major HM exerting remarkable anti‐H.
pylori effects, which exhibit profound anti‐inflammatory and anticancer
traits as well.
Agrimonia eupatoria L., rich in various polyphenols, exhibited 100%
anti‐ H. pylori effect at 50mg/ml by membrane damaging and suppression
of bacterial virulence factors. In addition, an ellagitannin‐enriched fraction
(hydrolyzable tannins) of Fragaria vesca extract could eradicate all the
isolates at 25mg/ml. Notably, these fractions exerted no inhibitory effect
on microbial flora but decrease the nitric oxide level as an inflammatory
mediator (Cardoso et al., 2018). Noticeably, intervenolin derivative AS‐
1934 could downregulate H. pylori urease (which protects bacteria from
gastric acid) and also suppressed the dihydroorotate dehydrogenase
enzyme (acting in de novo pyrimidine biosynthesis pathway), therefore
the application of compounds with similar inhibitory effects would be
promising (Ohishi et al., 2018).
Some similar properties have been observed among most of the
other HMs, which also protect gastric mucosa such as ginger, garlic
acid, cranberries, broccoli sprouts, green tea, and so forth (Table 2).
Several of promising and effective HM against H. pylori infection have
been exhibited in Table 2. In some biodiversity‐rich areas such as
China, Africa, India, and Iran the use of traditional herbs is most
common. Considering the strong association between gastric cancer
and H. pylori infection, anticancer properties of these compounds are
also promising. It is noteworthy that ethanolic, aqueous, and other
compounds of saffron (Crocus sativus L.) have exerted remarkable
anticancer effects through DNA synthesis inhibition, apoptosis, and
arrest of cell cycle both in vitro and in vivo (Abdullaev & Frenkel,
1992; Tavakkol‐Afshari, Brook, & Mousavi, 2008). Noticeably, crocin
(in vitro against MCF, MDA‐MB‐231, MCF‐7, HL‐60, K562, C3H10T1/
2, A549, VA13, MIA‐PaCa‐2, and Ascpc1 cancer cell lines and in vivo
on mice, Syrian mice, rats, and Athymic mice), crocetin (in vitro on
MCF, MDA‐MB‐231, MCF‐7, HL‐60, K562 and in vivo on mice, rats,
and Syrian mice), safranal and picrocrocin have displayed anticancer
traits (Chryssanthi et al., 2007; Hariri, Moallem, Mahmoudi, &
Hosseinzadeh, 2011; Magesh, Singh, Selvendiran, Ekambaram, &
Sakthisekaran, 2006; Mousavi, Tavakkol‐Afshari, Brook, & Jafari‐
Anarkooli, 2009; Noureini & Wink, 2012).
The aqueous and ethanolic extracts and other compounds of
Peganum harmala L seeds have exhibited profound anticancer
effects. Alkaloid derivatives, harmine, and harmaline decrease or
inhibit the growth of cancer cells by induction of apoptosis in a
dose‐dependent manner (Bernardo et al., 2012; Hamsa & Kuttan,
2011). In addition, they act as apoptotic inducers through
TABLE 1 Anti‐inflammatory and anticancer mechanisms of curcumin in vitro and in vivo
Antioxidant effects Inhibition and eradication of free radicals.
Inhibition of iNOS gene at low concentration.
Inflammatory signals IKBα phosphorylation inhibition and NF‐κB formation or its transmission.
Curcumin is not able to exert this effect in the form of a complex with the UPS system.
Inhibition of NF‐κB, MAPK, ERK, PI3K, and protein kinase B expression.
Cell cycle regulation Via CDKs, Cki(P27, P21), cyclin D, CDK1, CDK2, and CD25.
Inhibition and cleavage of CD1 promoter and Rb phosphorylation, preventing EF‐2 target genes expression.
Expression of antiapoptotic proteins IAP, XI, BCL, and BCL2.
Inhibition of IL‐1, IL‐16, IL‐18, chemokines, TNF‐α, and MMPs.
Inhibition of cdc25A phosphatase.
Repair in enzyme functions LOX and COX‐2.
Adhesins Inhibition of adhesin molecules such as ICAM‐1, VCAM, E‐selectin, and MMPs.
Note. ERK: extracellular signal‐regulated kinase; IL‐1: interleukin 1; MAPK: mitogen‐activated protein kinase; MMP: matrix metalloproteinase;
NF‐κB: nuclear factor‐κB; PI3K: phosphoinositide 3‐kinase; TNF‐α: tumor necrosis factor α; UPS: XXX; VCAM: vascular cell adhesion molecule.
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TABLE 2 Herbal medicines and their active fragments with plausible effects against H. pylori infection
Scientific names Family Extract fraction/compound References
Acacia nilotion Fahaceae Acetone methanol Amin, Anwar, Naz, Mehmood, and Saari (2013)
Alchornea triplinervia Euphorbiaceae methanol Lima et al. (2008)
Arrabidaea chica Bignoniaceae Hydroethanolic Mafioleti, da Silva Junior, Colodel, Flach, and
Martins (2013)
Artemisia absinthium Asteraceae Artemisinin, quercetin, isorhamnetin, camphor,
alpha‐pinene, saponins, germacrene‐D
Samuelsen (2000)
Bridelia micrantha Euphorbiaceae Acetone, ethyl acetate Okeleye, Bessong, and Ndip (2011)
Cabphyllum brasiliesnse Clusiaceae Hydroethanolic, dichloromethane,
chromanone acid
Souza et al. (2009); Lemos et al. (2012)
Calotropis procera Asclepiadoieae Acetone, methanol Amin et al. (2013)
Camellia sinensis Theaceae Methanol Hassani et al. (2009)
Chamomilla recutita Asteraceae Methanol Shikov, Pozharitskaya, Makarov, and
Kvetnaya (2008)
Cichorium intybus Composite Lacton sescoetrepens Meimandi and Yaghoobi (2015); Stamatis
et al. (2003)
Cinnamomum verum Lauraceae Cinnamaldehyde Ali et al. (2005); Hosseininejad et al. (2011)
Cocculus hirsutus Menispermaceae Ethanol Perumal Samy and Chow (2012)
Combretum molle Combretceae Acetone Njume, Jide, and Ndip (2011)
Croucus sativus Iridaceae Carotenoids, monoterpenes, aldehydes, crocetin,
crocins, safranal, picrocrocin
Kim et al. (2011); Stamatis et al. (2003)
Cuminum cyminum Apiaceae Ethanol Nostro et al. (2005)
Cyrtocarpa procera Anacaxliaceae dichloromethane, dichloromethane–MeOH
methanolic
Escobedo‐Hinojosa, del Carpio, Palacios‐
Espinosa, and Romero (2012)
Daucus carota Apiaceae Oil Bergonzelli, Donnicola, Porta, and Corthesy‐
Theulaz (2003)
Derris trifoliate Fahaceae Petroleum, chloroform, methanol Uyub, Nwachukwu, Azlan, and Fariza (2010)
Desmostachya bipinnata Poaceae Methanol ethyl acetate Ramadan and Safwat (2009)
Dittrichia viscosa Asteraceae Methanol Miguel, Faleiro, Cavaleiro, Salgueiro, and
Casanova (2008); Stamatis et al. (2003)
Eucalyptus torelliana Myrtaceae Chloroform, methanol Adeniyi, Odufowoke, and Olaleye (2006)
Eugenia caryophillus Myrtaceae Ethanol Ali et al. (2005); Li, Xu, Zhang, Liu, and Tan (2005)
Geranium wilfordii Geraniaceae Ethanol ethyl acetate X. Q. Zhang et al. (2013)
Glycyrrhiza uralensis Fahaceae Methanol Fukai et al. (2002)
Hancornia speciosa Apocynaceae Hydroalcoholic Moraes et al. (2008)
Hydrastis canadensis Ranunculaceae Methanol Mahady, Pendland, Stoia, and Chadwick (2003)
Lagenaria siceraria Cucurbitaceae Phocostrol, compserol, saponins Hajian (2016)
Mallotus phillipinensis Euphorbiaceae Ethanol Zaidi, Yamada, Kadowaki, Usmanghani, and
Sugiyama (2009)
Myrstica fragrans Myristicaceae Methanol Bhamarapravati, Pendland, and Mahady (2003);
Mahady et al. (2005)
Myrtus communis Myrtaceae Oil Deriu et al. (2007)
Persea americana Lauraceae Methanol Castillo‐Juárez et al. (2009)
Pistacia lentiscus Anacaxliaceae Triterpenic acids Paraschos et al. (2007)
Plantago major Plantaginaceae Caffeic acid, flavonoids, alkaloids, terpenoids Chiang, Chiang, Chang, Ng, and Lin (2002)
Plumhago zeylanica plumhaginaceae Ethanol, acetone, ethyl acetate Wang and Huang (2005a)
Potentilla fruticosa Rosaceae Ethanol Wang and Huang (2005b)
Prunus dulcis Rosaceae Polyphenol Tomczyk, Leszczyńska, and Jakoniuk (2008)
Punica granatum Lythraceae Ethanol, methanol, butanol Voravuthikunchai, Limsuwan, and Mitchell (2006)
(Continues)
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disruption of the respiratory chain by caspases (Mani, Taneja,
Jain, & Singh, 2018; Mohammad, 2018), the release of apoptosis
inducers, the inactivation of topoisomerase enzymes 1 and 2
(Mashhadi, Salimi, Forouzandeh, & Naghsh, 2016), fragmentation,
and chromatin density by caspase 6 by breaking down of the
structural nuclear protein and nuclear membrane lamina (3, DNA
fragmentation and disturbance in the process of cell division by
harmine, inhibition of the cell cycle via the G2 stage arrest
through harmine‐mediated P53 activation inhibiting tumorigeni-
city and reduction of membrane potential and mitochondrial ATP
levels by harmalacidin (Rüben, Panstruga, & Becker, 2015).
Furthermore, these compounds inhibit DNA synthesis/replication
through DNA synthesis enzymes inactivation (topoisomerase by
harmine) and cell division inhibition, inhibition of differentiation
of malignant and myeloid immature cells into neutrophils and
monocytes by ataxia telangiectasia and Rad3‐related (ATR)
proteins and vitamin D3. Notably, Β‐carboline‐mediated inhibition
of the DNA synthesis and DNA helix intercalate leading to
inhibition of the DNAs topoisomerases‐1 and 2 and the growth
inhibition of cancer cells in mice was confirmed. In addition, the
inhibitory effect on the DNA and RNA synthesis was exerted
through the creatine phosphokinase (CPK) effect of topoisome-
rase enzyme inhibition in the G1 phase of cell division (Kadhim,
Aziz, & Hadi, 2016; Shu et al., 2019).
Garlic compounds such as diallyl sulfide (NAG‐1 proapoptotic
gene induction), methyl allyl trisulphide (inhibition of benzo‐pyrene
and lipoxygenase in cancer cells), S‐methyl‐1‐systein sulphoxide, and
methiin (cell cycle arrest) are associated with epithelial cancer cell
apoptosis and cell cycle arrest (Kaowinn et al., 2018; Moosavi et al.,
2016; G. Wang, Liu, Ye, Fu, & Zhang, 2016).
It has been highlighted that silymarin compounds have cancer
regression or anticancer effects. In particular, silybum has inhibitory
effects in epidermal and prostate cells and also mouse and animals
breast cancer in vitro and in vivo (Padma et al., 2019). Silymarin has
conferred cytoprotective effect on human prostate and breast cells
exposed to carcinogens (Chandrasekar, Sivagami, & Babu, 2018). It has
shown synergistic effects with adriamycin on preventing cancer cell
growth. In the case of breast and lung cancer cells in humans, silybum
exacerbated the cytotoxic effects of cisplatin and doxorubicin. In
addition, it is promising that the stimulatory effects of silymarin were
exerted on liver normal cells DNA but not on cancer cells in rats with
hepatoma and did not stimulate tumor growth. In human studies with
hepatocellular carcinoma, after healing with silymarin, the disease was
improved daily. Nanoformulation of silymarin eliminated tumors via
increasing SOD, CAT, and GSH concomitant with decreasing MDA (El‐
Far, Salah, Essam, Abd El‐Azim, & El‐Sherbiny, 2018). The anticancer
and anti‐inflammatory effects of common HM fractions have been
demonstrated in Figures 1-3.
As outlined in Tables 2 and 3, major anti‐H.pylori HM
compounds exert anti‐inflammatory traits, which are pivotal for
gastroprotection. These effects are conferred mostly through the
phosphorylation of Akt and endothelial nitric oxide synthase,
nitrous oxide (NO), and HO‐1 induction through NF‐E2‐related
factor 2 signaling pathways, apoptosis induction through c‐Jun N‐
terminal kinase pathway, activation, and mitochondrial Bax
translocation, decrease of TNF‐α, IL‐1β, IL‐6, MCP‐1, and IL‐12
and increase of IL‐10 and TGF‐β1.
HM are mainly used to stimulate mucosal cells, inhibit
acid secretion, antioxidant production, and also through
HK‐ATPase.
TABLE 2 (Continued)
Scientific names Family Extract fraction/compound References
Rosa damascena Rosaceae Quercetin, camphor, geraniol Kodouri and Tabaei (2007)
Salvia officinalis Lamiaceae Alfa‐terpineol, Beta‐pinene, cineole Aleebrahim‐Dehkordy et al. (2017);
Hajimahmoodi et al. (2011); Moghaddam (2011)
Salvia mirzayanii Lamiaceae Methanol Atapour et al. (2009)
Sanguinaria canadensis Papaveraceae Methanol Mahady et al. (2003)
Scleria striatinux Cyperaceae Methanol Ndip et al. (2007)
Stachy setifera Lamiaceae Methanol Khanavi et al. (2008)
Silybum marianum Asteraceae Silymarins Aleebrahim‐Dehkordy et al. (2017)
Terminallia chebula Combretaceae Alkohol Malekzadeh, Ehsanifar, Shahamat, Levin, and
Colwell (2001)
Thymus kotschyanus Lamiaceae Thymol, carvacrol Aleebrahim‐Dehkordy et al. (2017)
Trachyspermum copticum Apiaceae Petroleum, benzene/diethyl methanol/diethyl Nariman, Eftekhar, Habibi, and Falsafi (2004);
Nariman et al. (2009)
Tribulus terrestris Zygophyllaceae Steroids, saponins, flavonoids, alkaloids, sterol,
phenol compound
Ivanova et al. (2009)
Zataria multiflora Lamiaceae Oil Hosseininejad et al. (2011)
Note. The HM compounds in Table 2 have exerted anti‐H. pylori, anticancer, anti‐inflammatory, and antioxidant properties. They act through induction of
cancer cell apoptosis, inhibition of proinflammatory cytokines and related kinases expression and other mechanisms or cell circuits hindering cell growth
in vitro and in vivo.
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↓ HK-Atpase activity and gastrin → ↓ acid secretion
↓Nitric oxide synthase
↑bFGF, EGF and EGFR → ↑ proliferation









According to the studies, herbal‐based therapies both in animal
models and in human models have been shown to be equally
effective with drugs such as omeprazole and cimetidine but the
Western Medical System still treats antibiotic‐based regimens for the
treatment of gastrointestinal disturbances caused by H. pylori (Bi,
Man, & Man, 2014).
The statistics have demonstrated that out of every 10 people
with cancer, about six people use HM along with traditional therapies
for cancer. Currently, there is almost no solid medical reason for the
use of HM in treating or preventing cancers. However, there is still a
widespread study of effective HM for preventing cancer, reducing its
symptoms and/or side effects and even treating it (Bi et al., 2014).
According to a review evaluating studies on the impact of
Chinese HM on reducing the side effects of chemotherapy in people
with intestinal cancer, it was suggested that a herbal remedy known
as “Huang Qi” contains compounds that reduce the side effects of
chemotherapy. In addition, there are reasons to suggest that HM
stimulate the immune system cells but do not affect the level of
antibodies in the blood (Safavi, Shams‐Ardakani, & Foroumadi, 2015).
Researchers continue to believe that extensive clinical trials are
needed to confirm the usefulness of HM in the treatment or
prevention of cancer, and to unravel HM with the potential of
application along with conventional therapies for cancer elimination.
Moreover, some herbs or herbal extracts tested in laboratories
indicate that they have anticancer effects, so they become anticancer
drugs but there is no scientific evidence from human experiments on
the effect of HM on cancer treatment. At the same time, Carctol and
Chaparral can be mentioned in the variety of herbal remedies that
some claim to be effective in treating cancer. On the other hand, it is
important to note that some herbal remedies can interfere with the
common therapies that are prescribed by physicians for treating
cancer, such as chemotherapy, radiotherapy, biological therapy, or
hormone replacement therapy. Several adverse effects of these
compounds have been observed such as severe kidney failure,
increased prothrombin times, intracranial hemorrhages, fatal case of
interstitial pneumonia, etc., (Safavi et al., 2015). Assessing previous in
vitro and in vivo studies, those predominant anti‐H. pylori HM
fractions with specific cellular mechanisms (anti‐inflammatory
and anticancerous pathways) have been depicted in Table 3 (Al‐
Sayed, Gad, El‐Shazly, Abdel‐Daim, & Nasser Singab, 2018; Arreola
et al., 2015; W. Chen et al., 2014; Chowchaikong, Nilwarangkoon,
Laphookhieo, Tanunyutthawongse, & Watanapokasin, 2018; Han,
Zhang, Deng, Lei, & Tan, 2016; Herrera‐Aco et al., 2019; Jamuna
et al., 2015; Jin, 2016; Salehi et al., 2018; Schäfer & Kaschula, 2014;
Shin et al., 2013; Taher et al., 2016; Q. Wang et al., 2017; Zou et al.,
2017). The formulation of these fractions will open new venues
toward efficient therapies.
3.1 | Future perspectives
It seems that the combination of HM compounds with antimicrobials
and even with anti‐inflammatory medicines is promising, opening new
insights in vitro and in vivo studies and clinical trials toward achieving
F IGURE 1 The anticancer and
anti‐inflammatory properties of HM
contributing to the healing of
H. pylori‐induced cell carcinoma and cancer
progression of a cell. HM: herbal medicine;
IFN‐γ: interferon‐γ; IL‐6: interleukin 6;
MAPK: mitogen‐activated protein kinase;
NF‐κB: nuclear factor‐κB; TNF‐α: tumor
necrosis factor α [Color figure can be
viewed at wileyonlinelibrary.com]
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proper therapeutic approaches without side effects. In addition,
pharmacological qualities and safety of HM need to be clarified. The
World Health Organization has not introduced an exact amount of HM
and conditions/mechanisms of resistance to them, thus future studies
are helpful to achieve a standard amount unraveling their pharmaco-
kinetics and pharmacodynamics. Furthermore, mechanisms of
resistance to these compounds are yet to be elucidated. For example,
curcumin had MIC (Osato, et al., 2001) value of between 5 and
50 µg/ml against 65 clinical isolates of H. pylori (the antimicrobial
activity of curcumin against H. pylori isolates from India and during
infections in mice). However, some studies have poor effectiveness of
curcumin and its combination with pantoprazole, N‐acetylcysteine, and
lactoferrin for the eradication of H. pylori. In vivo studies have
demonstrated the significant effect of this compound against
inflammation and H. pylori infection. Furthermore, gastroprotective
HM is helpful, which can be prescribed combined with 7probiotics. It
F IGURE 2 The anticancer exertion
mechanisms of HM fractions. Akt: protein
kinase B; ERK: extracellular
signal‐regulated kinase; HM: herbal
medicine; MAPK: mitogen‐activated
protein kinase; NF‐κB: nuclear factor‐κB;
PI3K: phosphoinositide‐3‐kinase [Color
figure can be viewed at
wileyonlinelibrary.com]
F IGURE 3 The anticancer and anti‐inflammatory mechanisms of curcumin on cellular circuits (Boyanapalli et al., 2018; Lin & Lin, 2008). Akt:
protein kinase B; JNK: c‐Jun N‐terminal kinase; MAPK: mitogen‐activated protein kinase [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 3 Anti‐inflammatory and anticancer cellular mechanisms of major anti‐H. pylori HM fractions
HM fraction Study Cellular mechanisms
Anti‐
inflammatory Anticancerousb
Allicin (garlic powder)a In vivo Increasing the phosphorylation of Akt and endothelial nitric
oxide synthase (eNOS), NO, and HO‐1 induction through
NF‐E2‐related factor 2 (Nrf2) signaling pathways. Apoptosis
induction through JNK pathway activation and mitochondrial
Bax translocation. The decrease of TNF‐α, IL‐1β, IL‐6, MCP‐1,
and IL‐12. An increase of IL‐10 and TGF‐β1
Yes Yes
Allicin In vivo Yes Yes
Diallyl disulfide In vivo Reduction in PGs, NO, IL‐1β, IL‐6, MCP‐1, IL‐12, and TNF‐α
levels; increase in IL‐10 levels; inhibition of COX‐2, iNOS, and
NF‐κB activity.
Yes Yes
Diallyl tetrasulfidea In vivo Reduction in IL‐1β, IL‐6, TNF‐α, NO, and PGs levels; inhibition
of COX‐2 and iNOS activity.
Yes Yes
Scopoletin In vitro iNOS, IL‐1β, IL‐6, and COX‐2 downregulatory effects Yes ND
Haemanthamine and
haemanthidine
In vivo Inhibition of cytokines production and apoptosis. Yes Yes
Alkaloids In vivo Significant reduction in IL‐1β, IL‐6, TNF‐α, NO, and PGs levels;
significant inhibition of COX‐2, iNOS, and NFκB activity.
Yes Yes
Scopolin In vivo TNF‐α, IL‐1β, and IL‐6 reduction; modulation of COX or PGE2
actions.
Yes Yes
Licoricidin In vivo IL‐6, IL‐1β, IL‐12, iNOS, and COX‐2 downregulatory effects. Yes Yes
Licoisoflavone In vivo iNOS and COX‐2 downregulatory effects. Yes Yes
Fuscaxanthone I In vivo ND ND ND
Beta‐mangostin In vivo TLR4‐mediated NF‐κB and MAPK signaling pathway. Yes Yes
Fuscaxanthone A – ND ND ND
Cowanin In vivo PCs regulation. Yes ND
Cowaxanthone In vivo phosphorylation and activation of Akt. Yes ND
Alpha‐mangostin In vivo Decreases the activation state of dendritic cells and its
production of Th1‐type cytokines diminishes the IL‐6
production apoptosis in Th1 and Th17‐polarized
lymphocytes.
Yes Yes
Cowanol – ND ND ND
Isojacareubin In vivo PCs regulation Yes ND
Fuscaxanthone G In vivo ND ND ND
Nigrolineabiphenyl B In vivo PCs regulation Yes
1,3,5,6‐Tetrahydroxyxanthone – ND ND ND
Vokensiflavone In vivo PCs regulation Yes ND
Morelloflavone In vivo NO decrease by MQs reducing IL‐6, TNF‐α, and IL‐1β. Yes Yes
Berberine In vivo AMPK activation, NFB inhibition, AP‐1 pathway inhibition
leading to inhibition of PCs expression.
Yes ND
‐Hydrastine – ND ND ND
Sanguinarine In vitro Reducing the TNF‐α, IL‐6, IL‐18, IL‐12, and AMPK/Smad1
signaling pathway.
Yes Yes
Chelerythrine In vivo Through the NF‐κB signaling pathway mediated by Nrf2 and
MAO inhibition.
Yes Yes
Protopine In vivo IL‐6, IL‐1β, IL‐12, iNOS, and COX‐2 downregulatory effects. Yes ND
Palmatinea In vivo IL‐6, IL‑1α, IL‐1β, IL‑8, IL‐12, and iNOS decrease
granulocyte‑colony stimulating factor and granulocyte
macrophage colony‑stimulating factor TRIF‐dependent
NF‐κB pathway M2‐macrophagic polarization and STAT6
activation
Yes Yes
Note. Akt: protein kinase B; AMPK: 5ʹ AMP‐activated protein kinase; HO‐1: heme oxygenase‐1; IL‐1β: interleukin 1β; JNK: c‐Jun N‐terminal kinase; MAO:
monoamine oxidase; MAPK: mitogen‐activated protein kinase; MQs: macrophages; ND, not determined; NF‐κB: nuclear factor‐κB; NO: nitrous oxide; PCs:
proinflammatory cytokines; PG: prostaglandin; TGF‐β1: transforming growth factor‐β1; TNF‐α: tumor necrosis factor α.
aMIC was 3–6 µg/ml, thus being most effective anti‐H. pylori bioactive compounds.
bIf yes, both in vitro and in vivo studies have unraveled the anticancer effects of these fractions.
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was elucidated that phenol metabolites act as prebiotics. Noticeably,
the oral bioavailability, solubility, absorption, and lower metabolism of
compounds should also be evaluated in vivo, where nanocarriers are
promising insights for this purpose (Aleebrahim‐Dehkordy et al.,
2017). Future investigations for designation of efficient vaccines
against bacterial virulence factors (vacA and cagA) can be a suitable
approach for contamination inhibition. It is worth considering that
some microRNAs (miRNAs) increase during chronic gastritis and
gastric cancer induced by H. pylori such as miR‐328, miR‐223, miR‐21,
mir‐30d, miR‐222, miR‐9, miR‐96, miR‐146a and miR‐650, miR‐34c
and miR‐223‐3p. However, some exert reverse or suggested anti‐
inflammatory or anticancer effects such as mir‐328, miR‐155 and miR‐
146b, miR‐223, miR‐212‐3p and miR‐361‐3p, miR‐27b, miR‐141, miR‐
3178, miR‐34b/c and miR‐133a, miR‑375, miR‐203, miR‐30a and miR‐
204. Recent advent of knowledge of miRNAs participating in various
cellular circuits has made it possible to target and downregulate
inflammatory miRNAs and upregulate those anti‐inflammatory miR-
NAs to protect the gastric mucosa.
4 | CONCLUSION
Induction of proinflammatory pathways plays a crucial role in the
chronic inflammation and gastric carcinoma and H. pylori pathogen-
esis. HM and their bioactive compounds are nontoxic, inexpensive,
and mostly anti‐inflammatory, reminding meticulous emphasis on the
elimination of H. pylori and gastric cancer. Several HM has exerted
paramount anti‐H. pylori traits. In addition, they exert anti‐inflam-
matory effects through several cellular circuits such as inhibition of
5ʹ‐adenosine monophosphate‐activated protein kinase, NF‐κB, and
activator protein‐1 pathway activation leading to the inhibition of
proinflammatory cytokines (IL‐1α, IL‐1β, IL‐6, IL‐8, IL‐12, INF‐γ, and
TNF‐α) expression. Furthermore, they inhibit NO release and COX‐2
and iNOS activity. The apoptosis induction in Th1 and Th17‐polarized
lymphocytes and M2‐macrophagic polarization and STAT6 activation
has also been exhibited. Although the effectiveness of HM has been
exhibited in vitro and in vivo, the combination of these compounds
with antimicrobials and even with anti‐inflammatory drugs can be
helpful in terms of prevention of side effects and antimicrobial
resistance. Future clinical trials are also necessary to be investigated
for revealing their pharmacokinetics. In the aspect of bioavailability,
solubility, absorption, and metabolism of herbal compounds nano-
carriers such as loading on poly lactideco‐glycolide and nanoparticle
formulations are helpful. Those gastro‐protective and anti‐inflamma-
tory compounds such as curcumin, ginger, garlic acid, and cranberries
have demonstrated appropriate anti‐H. pylori properties. Application
and employment of combined therapies composed of probiotics and
drugs can also be examined for better clearance of gastric mucosa. In
addition, downregulation of inflammatory miRNAs and upregulation
of those anti‐inflammatory miRNAs using HM is proposed to protect
the gastric mucosa.
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